Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 457


Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.

Santarpia M, Gil N, Rosell R.

Expert Rev Clin Pharmacol. 2015 Jul;8(4):461-77. doi: 10.1586/17512433.2015.1055252. Epub 2015 Jun 11.


The two sides of border disease in Pyrenean chamois (Rupicapra pyrenaica): silent persistence and population collapse.

Marco I, Cabezón O, Velarde R, Fernández-Sirera L, Colom-Cadena A, Serrano E, Rosell R, Casas-Díaz E, Lavín S.

Anim Health Res Rev. 2015 Jun;16(1):70-7. doi: 10.1017/S1466252315000055.


A randomised double blind clinical trial to compare surgical field bleeding during endoscopic sinus surgery with clonidine-based or remifentanil-based hypotensive anaesthesia.

Cardesin A, Pontes C, Rosell R, Escamilla Y, Marco J, Escobar MJ, Bernal-Sprekelsen M.

Rhinology. 2015 Jun;53(2):107-15. doi: 10.4193/Rhin14.185.


A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1).

Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, Samarzija M, Felip E, Ciuleanu T, Hirsh V, Wehler T, Spicer J, Salgia R, Shapiro G, Sheldon E, Teofilovici F, Vukovic V, Fennell D.

Ann Oncol. 2015 May 21. pii: mdv220. [Epub ahead of print]


The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer.

Karachaliou N, Molina-Vila MA, Rosell R.

Expert Rev Respir Med. 2015 Jun;9(3):241-4. doi: 10.1586/17476348.2015.1046439. Epub 2015 May 20.


Postnatal persistent infection with classical Swine Fever virus and its immunological implications.

Muñoz-González S, Ruggli N, Rosell R, Pérez LJ, Frías-Leuporeau MT, Fraile L, Montoya M, Cordoba L, Domingo M, Ehrensperger F, Summerfield A, Ganges L.

PLoS One. 2015 May 4;10(5):e0125692. doi: 10.1371/journal.pone.0125692. eCollection 2015.


Relationship between gene mutation and lung cancer metastasis.

Rosell R, Karachaliou N.

Cancer Metastasis Rev. 2015 May 5. [Epub ahead of print]


Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river's DELTA?

Morales-Espinosa D, Rosell R.

J Thorac Dis. 2015 Mar;7(3):227-9. doi: 10.3978/j.issn.2072-1439.2015.01.34. No abstract available.


Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.

Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, Kratzke R, Graziano SL, Popper HH, Rosell R, Douillard JY, Le-Chevalier T, Pignon JP, Soria JC, Brambilla EM.

J Clin Oncol. 2015 Apr 27. pii: JCO.2014.58.8335. [Epub ahead of print]


Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla RJ, Yang JC.

J Clin Oncol. 2015 Jun 10;33(17):1958-65. doi: 10.1200/JCO.2014.58.1736. Epub 2015 Apr 20.


AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J.

Cancer Cell. 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010.


ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf J.

Oncotarget. 2015 Apr 30;6(12):10577-85.


Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.

Santarpia M, Altavilla G, Pitini V, Rosell R.

Future Oncol. 2015;11(8):1259-74. doi: 10.2217/fon.14.320.


Real-time liquid biopsies become a reality in cancer treatment.

Karachaliou N, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R.

Ann Transl Med. 2015 Mar;3(3):36. doi: 10.3978/j.issn.2305-5839.2015.01.16. No abstract available.


The epidermal growth factor receptor (EGRF) in lung cancer.

Carcereny E, Morán T, Capdevila L, Cros S, Vilà L, de Los Llanos Gil M, Remón J, Rosell R.

Transl Respir Med. 2015 Feb 24;3:1. doi: 10.1186/s40247-015-0013-z. eCollection 2015.


A critical question for cancer therapy: what new targets exist?

Rosell R, Karachaliou N, Codony J, Teixido C, Garcia-Roman S, Morales D, Cao MG, Viteri S, Veliz I, Loo Y, Castillo O.

Transl Lung Cancer Res. 2014 Dec;3(6):384-8. doi: 10.3978/j.issn.2218-6751.2014.08.10.


ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.

Karachaliou N, Gimenez-Capitan A, Drozdowskyj A, Viteri S, Moran T, Carcereny E, Massuti B, Vergnenegre A, de Marinis F, Molina MA, Teixido C, Rosell R.

Transl Lung Cancer Res. 2014 Jun;3(3):122-30. doi: 10.3978/j.issn.2218-6751.2014.03.02.


Predicting resistance by selection of signaling pathways.

Karachaliou N, Rosell R, Molina MA, Viteri S.

Transl Lung Cancer Res. 2014 Apr;3(2):107-15. doi: 10.3978/j.issn.2218-6751.2014.02.04. Review.


Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.

Teixidó C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R.

Transl Lung Cancer Res. 2014 Apr;3(2):70-4. doi: 10.3978/j.issn.2218-6751.2014.02.02. Review.


10(th) Congress on Lung Cancer-updates on clinical trials: goal.

Campelo RG, Massuti B, Mosquera J, Rosell R.

Transl Lung Cancer Res. 2014 Apr;3(2):66-9. doi: 10.3978/j.issn.2218-6751.2014.02.05. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk